Daclizumab [152923-56-3]

TargetMol Chemicals

Daclizumab [152923-56-3]

9

152923-56-3

Research Use Only

Daclizumab

SDS-PAGE:95% SEC-HPLC:99.99%

Daclizumab (Zenapax) is a humanized monoclonal antibody that specifically inhibits the alpha subunit of IL-2R-HA. Daclizumab (Zenapax) can inhibit the binding of IL-2 and IL-2R-HA through specific binding to CD25. Daclizumab (Zenapax) studies multiple sclerosis.

3 years

-20°C

12352203